Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies

Figures & data

Table 1 Demographic and Baseline Clinical Characteristics of SONATA and RWE Chart Review Studies

SONATA
Demographics Characteristics	Lifitegrast (n=211)	Placebo (n=111)
Age, years
Mean (±SD)	58.8 (±12.39)	61.0 (±13.18)
≥75 years, n (%)	19 (8.6)	15 (13.5)
Female, n (%)	165 (74.7)	85 (76.6)
Ethnicity, n (%)
Hispanic or Latino	33 (14.9)	17 (15.3)
Race, n (%)
White	176 (79.6)	92 (82.9)
RWE Chart Review
Demographic characteristics	Lifitegrast (N=600)
Age, years (at index date)
Mean (±SD) [95% CI]	57.1 (±12.8) [56.1, 58.1]
Age range, n (%) [95% CI]
18–34	34 (5.7) [4.0, 7.8]
35–49	129 (21.5) [18.3, 25.0]
50–64	278 (46.3) [42.3, 50.4]
65–69	70 (11.7) [9.2, 14.5]
70–74	50 (8.3) [6.2, 10.8]
75–79	25 (4.2) [2.7, 6.1]
80–84	8 (1.3) [0.6, 2.6]
≥85	6 (1.0) [0.4, 2.2]
Female, % (95% CI)	75.8 (72.2, 79.2)
Type of DED, % (95% CI)
Evaporative deficiency only	62.7 (58.7, 66.5)
Aqueous deficiency only	5.3 (3.7, 7.4)
Both evaporative and aqueous deficiency	26.7 (23.2, 30.4)
Ocular Disease/Conditions, % (95% CI)
Amblyopia	1.2 (0.5, 2.4)
Cataract	33.8 (30.1, 37.8)
Glaucoma	5.5 (3.8, 7.6)
Macular degeneration	4.0 (2.6, 5.9)
Previous ocular iInjury	2.5 (1.4, 4.1)
Strabismus	0.5 (0.1, 1.5)
Other*	4.8 (3.3, 6.9)
None	55.7 (51.6, 59.7)
Unknown	0.3 (0.0, 1.2)
Contact Lens Usage, % (95% CI)
Daily Ddisposable	12.0 (9.5, 14.9)
Weekly disposable	5.0 (3.4, 7.1)
Monthly disposable	6.7 (4.8, 9.0)
Disposable soft	2.2 (1.2, 3.7)
Extended wear	0.7 (0.2, 1.7)
Gas permeable	1.3 (0.6, 2.6)
None	73.0 (69.3, 76.5)
Unknown	0.2 (0.0, 0.9)

Notes: *Included allergic conjunctivitis, anatomically narrow angles, blepharitis, chalazion, conjunctivochalasis, corneal dystrophy, dermatochalasis, diabetic retinopathy, drusen, epiRetinal membrane, filamentary keratitis, giant papillary conjunctivitis, keratoconus, lagophthalmos, penetrating keratoplasty, posterior vitreous detachment, pseudophakia, pterygium, recurrent corneal erosion, retinal detachment, retinal hole, Stevens–Johnson syndrome, superficial punctate keratitis, and uveitis.

Abbreviations: CI, confidence interval; DED, dry eye disease; SD, standard deviation.

Figure 1 Proportion of patients who did not use artificial tears in the lifitegrast and placebo groups of the SONATA study (safety population).

Figure 2 Proportion of patients with DED-related treatments during the pre- and post-index period in the RWE chart review. *Only medication reported in the medical charts are reported as a post-index combination therapy with lifitegrast.

Table 2 DED Symptoms Reported During the Preindex and Postindex Periods in the RWE Chart Review Study

Symptoms	Preindex (n=600) % (95% CI)	Postindex (n=320) % (95% CI)
Blurred vision	57.7 (53.6, 61.7)	3.4 (1.7, 6.1)
Eye dryness	87.5 (84.6, 90.0)	5.0 (2.9, 8.0)
Foreign body sensation	49.8 (45.8, 53.9)	2.5 (1.1, 4.9)
Ocular stinging or burning	56.0 (51.9, 60.0)	2.5 (1.1, 4.9)
Ocular pain	12.2 (9.7, 15.1)	0.6 (0.1, 2.2)